Unicycive Therapeutics’ (UNCY) “Speculative Buy” Rating Reiterated at Benchmark

Benchmark reiterated their speculative buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. They currently have a $3.00 price target on the stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a buy rating and issued a $2.50 target price on shares of Unicycive Therapeutics in a research note on Tuesday, September 3rd. Brookline Capital Management raised shares of Unicycive Therapeutics to a strong-buy rating in a research note on Tuesday, July 9th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus price target of $5.13.

Unicycive Therapeutics Stock Up 0.2 %

UNCY opened at $0.35 on Friday. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82. The company has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.87. The stock has a market cap of $13.32 million, a P/E ratio of -0.30 and a beta of 2.34.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.08. On average, equities research analysts expect that Unicycive Therapeutics will post -0.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in Unicycive Therapeutics in the 1st quarter worth $36,000. BVF Inc. IL boosted its stake in shares of Unicycive Therapeutics by 70.5% during the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after buying an additional 1,493,462 shares during the last quarter. Finally, Rosalind Advisors Inc. acquired a new position in shares of Unicycive Therapeutics during the 1st quarter worth about $2,594,000. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.